You are here

At the cutting edge of biotechnology

iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions

BT_20200919_KOPIC19_4247600.jpg
"China is a high-priority market and big growth driver for us. Australian-made health supplements are regarded by Chinese consumers as the gold standard of products due to the country's reputation for safety and quality. We expect this market to grow from strength to strength." - Janakan Krishnarajah, COO, iX Biopharma.

SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.

Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes